Clinical trials: Pancreatic Cancer
Cancer, Solid Tumor
Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors
CRLX101 is a nanopharmaceutical comprised of the chemotherapeutic camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer.
- Trial name
- NCT00333502
- Testing
- Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer
- Where
- 3 sites in United States
- Volunteers
- 62 people
- Sponsor
- NewLink Genetics Corporation
Metastatic Pancreatic Ductal Adenocarcinoma
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitabine in all randomized patients.
- Trial name
- PRISM-1 (NCT06608927)
- Testing
- Quemliclustat, Nab-paclitaxel, Gemcitabine
- Where
- 111 sites in United States, Australia and 11 more
- Volunteers
- 610 people
- Sponsor
- Arcus Biosciences, Inc.
Carcinoma
Data Base Project for Acquisition of Cancer Patient Data in Practices and Ambulant Therapy
The purpose of this registry is to evaluate the situation regarding ambulant therapy of cancer patients in different practices in Germany.
- Trial name
- NCT02303353
- Where
- Germany
- Volunteers
- 2,000 people
- Sponsor
- SPGO Research Mannheim GmbH
Bladder Cancer, Pancreas Cancer
A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors
This multicenter, non-randomized, Phase II study will assess the efficacy, safety, and pharmacokinetics of trastuzumab emtansine in participants with HER2 overexpressing locally advanced (unresectable and not treatable with…
- Conditions
- Bladder Cancer, Pancreas Cancer, Cholangiocellular Carcinoma
- Trial name
- KAMELEON (NCT02999672)
- Testing
- Trastuzumab Emtansine
- Where
- 16 sites in Italy, Netherlands and 2 more
- Volunteers
- 20 people
- Sponsor
- Hoffmann-La Roche
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with…
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC)
- Trial name
- NCT07349537
- Testing
- RMC-5127, daraxonrasib, cetuximab
- Where
- 9 sites in United States
- Volunteers
- 574 people
- Sponsor
- Revolution Medicines, Inc.
Pancreatic Cancer
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis
Metastatic Pancreatic Cancer Disease is one of the most aggressive and deadliest forms of cancer with very poor survival. This study will evaluate adverse events and change in disease activity in participants 18 to 75 years of…
- Trial name
- NCT04807972
- Testing
- ABBV-927, Budiglimab, modified FOLFIRINOX
- Where
- 15 sites in United States, Australia and 4 more
- Volunteers
- 40 people
- Sponsor
- AbbVie
Pancreatic Cancer, Pancreatic Adenocarcinoma
Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates
The objective of this study is to estimate the R0 resection rate in patients with Resectable Pancreatic Ductal Adenocarcinoma (R-PDAC) as well as those with Resectable Pancreatic Ductal Adenocarcinoma (BR-PDAC) independently in…
- Conditions
- Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreas Ductal Adenocarcinoma
- Trial name
- NCT02723331
- Testing
- Nab paclitaxel, Gemcitabine
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Academic Thoracic Oncology Medical Investigators Consortium
Gastric Neoplasms, Pancreatic Neoplasms
Chromogranin A as Blood Marker in Cancer Patients
Gastroentero-pancreatic neuroendocrine tumors (GEP-NETs) are a heterogenous group of neoplasms that arise from enterochromaffin cells of the gastrointestinal (GI) tract and pancreas. They account for 50-70% of all incident NETs.
- Conditions
- Gastric Neoplasms, Pancreatic Neoplasms, Small Intestinal Neoplasms, Colorectal Neoplasms
- Trial name
- NCT03817866
- Testing
- BRAHMS CgA II KRYPTOR
- Where
- 4 sites in United States, Germany
- Volunteers
- 175 people
- Sponsor
- Brahms AG
Advanced Solid Tumors
A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors
The purpose of this study is to evaluate the tolerability and safety profile of ASP1948 when administered as a single agent and in combination with nivolumab or pembrolizumab in participants with locally advanced (unresectable)…
- Trial name
- NCT03565445
- Testing
- ASP1948, nivolumab, pembrolizumab
- Where
- 42 sites in United States, Canada and 7 more
- Volunteers
- 190 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma
Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.
Open-label, multi-center, non-randomized, multiple dose, safety, tolerability, pharmacokinetic, and pharmacodynamics and clinical activity study of PF-06940434 (Integrin alpha-V/beta-8 Antagonist) in patients with SCCHN (Squamous…
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Ovarian Cancer, Gastric Cancer
- Trial name
- NCT04152018
- Testing
- PF-06940434, PF-06801591
- Where
- 31 sites in United States, Australia and 3 more
- Volunteers
- 85 people
- Sponsor
- Pfizer
Pancreatic Cancer, Pancreatic Carcinoma
Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation
This study investigates the first-line treatment of advanced pancreatic cancer with KRAS G12D mutation.The study consists of two stages I, Stage I ：explores the combination dose and the second phase; Stage II ：patients were…
- Trial name
- NCT07656376
- Testing
- DN022150+AG( Stage I ）, DN022150+AG（Stage II）
- Volunteers
- 465 people
- Sponsor
- Jiangxi Kvvit Pharmaceutical Co., Ltd.
Pancreatic Ductal Adenocarcinoma
Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer
Patients with metastatic, locally advanced, or unresectable pancreatic ductal carcinomas (PDA) who have failed prior chemotherapy with gemcitabine regimens have an extremely poor prognosis with progression-free survival of around…
- Trial name
- NCT01580397
- Testing
- INNO-206
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- ImmunityBio, Inc.
Pancreatic Neoplasms
Intra-Arterial Treatment of Pancreatic Cancer Using the RenovoCath™ RC120 Catheter
This is an observational study to assess patient survival and clinical outcomes after the RenovoCath™ RC120 catheter is used to deliver chemotherapeutic agents to pancreatic tumors.
- Trial name
- NCT02591082
- Testing
- RenovoCath™ R120 Catheter
- Where
- 5 sites in United States
- Volunteers
- 25 people
- Sponsor
- RenovoRx
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with investigator-selected standard of care (SoC) therapy…
- Conditions
- GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors
- Trial name
- ACTION-1 (NCT05477576)
- Testing
- RYZ101, Everolimus, Sunitinib
- Where
- 54 sites in United States, Belgium and 6 more
- Volunteers
- 343 people
- Sponsor
- RayzeBio, Inc.
Cancer of Pancreas, Cancer of Liver
A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies
A Randomized, Double-Blind, Placebo-Controlled, Parallel, Multi-Center Study to Assess the Efficacy of BRCX014 Combined with Standard-Of-Care Treatment in Subjects with Glioblastoma Multiforme, Multiple Myeloma, and GI…
- Conditions
- Cancer of Pancreas, Cancer of Liver, Cancer of Rectum, Cancer of Colon
- Trial name
- NCT03607643
- Testing
- Cannabidiol, Bortezomib, Leucovorin
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Leaf Vertical Inc.
Solid Tumors, Pancreatic Cancer
CTS2190 Phase I /II Clinical Study in Patients
This is a first in human study in patients with advanced or metastatic solid tumors. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific tumor types.
- Conditions
- Solid Tumors, Pancreatic Cancer, Non-small Cell Lung Cancer, Triple-negative Breast Cancer
- Trial name
- NCT06224387
- Testing
- CTS2190 capsules
- Where
- 2 sites in China
- Volunteers
- 224 people
- Sponsor
- CytosinLab Therapeutics Co., Ltd.
Ovarian Cancer, Breast Cancer
'OLAP' (OLAparib Regulatory Post-marketing Surveillance)
The objectives of this study are to assess safety and effectiveness of Lynparza tablet (olaparib, hereinafter "the study drug") in a real world setting in patients who are prescribed with the study drug according to the approved…
- Conditions
- Ovarian Cancer, Breast Cancer, Prostate Cancer, Pancreatic Cancer
- Trial name
- OLAP (NCT04553926)
- Where
- 18 sites in South Korea
- Volunteers
- 661 people
- Sponsor
- AstraZeneca
Neoplasms
Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
Determine the safety, tolerability, and maximum tolerated dose (MTD) of IV administered VIP236 as monotherapy in patients with advanced solid tumor cancer
- Trial name
- NCT05712889
- Testing
- VIP236 (Q3W), VIP236 (Q2W)
- Where
- 6 sites in United States, Australia
- Volunteers
- 29 people
- Sponsor
- Vincerx Pharma, Inc.
Pancreatic Pseudocyst
A Study to Evaluate the Effectiveness and Safety of EUS-guided Transluminal Drainage With 'Niti-S SPAXUS Stent'
The purpose of this study is to evaluate the safety and effectiveness of endoscopic ultrasound (EUS)-guided transluminal drainage with 'Niti-S SPAXUS Stent' for the treatment of pancreatic pseudocyst.
- Trial name
- NCT02730663
- Testing
- Niti-S SPAXUS Stent
- Where
- 6 sites in South Korea
- Volunteers
- 36 people
- Sponsor
- Taewoong Medical Co., Ltd.
Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal
A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies
The purpose of this study is to learn about the safety and the effects of PF-08046037 alone or with sasanlimab for the treatment of certain advanced or metastatic malignancies.
- Conditions
- Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal, Malignant Melanoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Trial name
- NCT06974734
- Testing
- PF-08046037, sasanlimab
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 8 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.